16:00:11 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriLäkemedel & Handel
Nordic Nanovector är ett läkemedelsbolag. Bolaget specialiserar sig inom utveckling av antikroppsläkemedel för behandling utav hematologisk cancer. Störst specialisering återfinns inom precisionsterapi som används i den kliniska fasen. Övriga sjukdomar som behandlas är non-hodgkins lymfom (NHL). Bolaget grundades under 2009 och har sitt huvudkontor i Oslo.

Kalender

2021-11-18 Kvartalsrapport 2021-Q3
2021-08-27 Kvartalsrapport 2021-Q2
2021-08-26 Kvartalsrapport 2021-Q2
2021-05-26 Kvartalsrapport 2021-Q1
2021-04-28 Årsstämma 2021
2021-04-16 Ordinarie utdelning NANOV 0.00 NOK
2021-03-22 Extra Bolagsstämma 2021
2021-02-18 Bokslutskommuniké 2020
2020-11-19 Kvartalsrapport 2020-Q3
2020-10-21 Extra Bolagsstämma 2020
2020-08-27 Kvartalsrapport 2020-Q2
2020-06-11 Ordinarie utdelning NANOV 0.00 NOK
2020-06-10 Årsstämma 2020
2020-05-26 Kvartalsrapport 2020-Q1
2020-02-27 Bokslutskommuniké 2019
2019-11-19 Kvartalsrapport 2019-Q3
2019-08-22 Kvartalsrapport 2019-Q2
2019-05-23 Kvartalsrapport 2019-Q1
2019-04-26 Ordinarie utdelning NANOV 0.00 NOK
2019-04-25 Årsstämma 2019
2019-02-18 Extra Bolagsstämma 2019
2018-08-22 Kvartalsrapport 2018-Q2
2018-05-31 Ordinarie utdelning NANOV 0.00 NOK
2018-05-30 Årsstämma 2018
2018-05-30 Kvartalsrapport 2018-Q1
2018-02-27 Bokslutskommuniké 2017
2017-12-20 Extra Bolagsstämma 2017
2017-11-22 Kvartalsrapport 2017-Q3
2017-08-23 Kvartalsrapport 2017-Q2
2017-05-26 Ordinarie utdelning NANOV 0.00 NOK
2017-05-24 Kvartalsrapport 2017-Q1
2017-05-24 Årsstämma 2017
2017-02-28 Bokslutskommuniké 2016
2016-11-23 Kvartalsrapport 2016-Q3
2016-10-12 Extra Bolagsstämma 2016
2016-08-24 Kvartalsrapport 2016-Q2
2016-05-31 Kapitalmarknadsdag 2016
2016-05-20 Ordinarie utdelning NANOV 0.00 NOK
2016-05-19 Kvartalsrapport 2016-Q1
2016-05-19 Årsstämma 2016
2016-02-26 Bokslutskommuniké 2015
2015-11-17 Kapitalmarknadsdag 2015
2015-10-21 Kvartalsrapport 2015-Q3
2015-08-26 Kvartalsrapport 2015-Q2
2015-05-27 Kvartalsrapport 2015-Q1
2015-03-09 Årsstämma 2015
2014-11-12 Extra Bolagsstämma 2014
2020-10-21 11:37:28
Oslo, Norway, 21 October 2020

Nordic Nanovector ASA (the "Company") announces that an extraordinary general
meeting ("EGM") in the Company was held today at the Company's offices in
Kjelsåsveien 168B, 0884 Oslo. The EGM approved all items on the agenda,
including the authorisation to the board of directors to increase the share
capital in connection with a potential repair offering as announced on 23 and 30
September 2020, and the authorisation to the board of directors to increase the
share capital by up to 20%. The minutes from the EGM are attached and are also
available at www.nordicnanovector.com.

As previously announced, a repair offering is subject to (i) the prevailing
market price of the Company's shares not being lower than the subscription price
of NOK 17.50 as determined in the private placement resolved by the board of
directors on 23 September 2020 and (ii) relevant corporate resolutions being
passed by the Company, including the approval by the Board. The Company expects
to announce an update as to the implementation of a repair offering shortly.

For further information, please contact:

IR enquiries Malene Brondberg, CFO

Cell: +44 7561 431 762

Email: ir@nordicnanovector.com

Media Enquiries

Mark Swallow/Frazer Hall/David Dible (Citigate Dewe Rogerson)

Tel: +44 203 926 8535

Email: nordicnanovector@citigatedewerogerson.com

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of targeted therapies for
haematological cancers. Nordic Nanovector's lead clinical-stage candidate is
Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to
advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with
substantial unmet medical need, representing a growing market forecast to be
worth nearly USD 29 billion by 2026. Nordic Nanovector retains global marketing
rights to Betalutin® and intends to actively participate in the
commercialisation of Betalutin® in the US and other major markets.

Further information can be found at www.nordicnanovector.com.